J&J’s Janssen Pharmaceuticals Under Fire Again in Risperdal Trial

Johnson & Johnson’s Janssen Pharmaceuticals came under fire again when a Philadelphia jury awarded $70 million to the family of a boy who developed breasts while taking the company’s antipsychotic drug Risperdal. Apparently the jury found that Janssen intentionally falsified, destroyed or concealed evidence in the case in reaching its decision. These allegations come after J&J and Janssen already paid over $2.2 billion back in 2013 to resolve civil and criminal investigations by the U.S. Department of Justice into its marketing of Risperdal and several other drugs. The $70 million verdict here dwarfs the next largest jury award in a Risperdal case which was $2.5 million. Perhaps this could be a sign that people are tired of J&J and Janssen putting its revenues ahead of the health and well-being of its consumers. This trend in jury awards could be particularly troubling for the company as J&J is still facing over 12,000 claims regarding Risperdal.

Read more

Jury Awards $70 Million in Risperdal Trial

In early July, a jury in a Philadelphia courtroom awarded $70 million to the family of a boy who developed breasts after taking the antipsychotic drug Risperdal. The jury found that the maker of Risperdal, Janssen Pharmaceuticals, failed to warn the boy’s healthcare providers that there was a risk of gynecomastia (breast growth in men) with use of the drug. The boy’s lawyers say he developed gynecomastia at the age of five as a result of taking Risperdal. A Janssen spokeswoman said the $70 million award was “clearly excessive” and said the company plans on asking the court to review it.

Read more